Alethia Biotherapeutics

The company is located at 141, Président-Kennedy Ave., Suite SB-5100.

Alethia Biotherapeutics begins Phase 2 development of its EMT inhibitor **AB-16B5**, now authorized by the FDA. The company will test the drug in combination with docetaxel for patients with **metastatic non-small cell lung cancer (NSCLC)** who have progressed after prior treatment. The multi-center trial targets previously treated subjects with advanced disease.

May 2020BioSpaceNews article

Alethia Biotherapeutics secures **$4.7 million in financing** to develop its **bone antiresorptive therapy**. The funding supports advancement of preclinical or early-stage research aimed at treating bone-related conditions. The company focuses on addressing unmet medical needs in skeletal disorders through novel therapeutic approaches.

Nov 2012Fierce BiotechNews article

Alethia Biotherapeutics raises **C$9.6 million in Series A funding** to advance its pipeline of **therapeutic monoclonal antibody treatments**. The capital supports preclinical and clinical development of antibody-based therapies targeting unmet medical needs. The company focuses on leveraging its platform to design and optimize antibody candidates for diverse disease indications.

Sep 2010Fierce BiotechNews article

Alethia Biotherapeutics raises **C$9.6 million in Series A funding** to advance its monoclonal antibody pipeline. The Montreal-based company uses its **STAR platform** to discover therapeutic targets and will allocate proceeds toward transitioning lead pre-clinical programs into clinical development within the next 18 months.

Sep 2010BioSpaceNews article